anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In this group, complete hemostasis and cavity disinfection were achieved using a KTP laser (SMARLITE D, Deka, Calenzano FI, Italy). After initial hemorrhage control, complete hemostasis was achieved by exposure to a KTP laser (532 nm wavelength) in noncontact mode at 1.5 W of power with a pulse mode (Ton 100 ms, Toff 100 ms) for 2 s. The diameter of optical fiber was 300 μm. Laser application was repeated 3 times if required. After bleeding control was achieved, cavity disinfection was performed by laser application with a noncontact circular movement for 5 s using 1 W power and 300 nm tip.
This is a single center, randomized, therapeutic exploratory study to monitor wound healing with the new AltrazealTM flexible hydrogel nanoparticle dressing compared to the existing treatment standard (Aquacel ® AG sodium carboxymethylcellulose dressing) in patients with at least two skin graft donor sites. 40 patients with at least 2 skin graft donor sites, ranging in age from 3 and 85 years, will be enrolled. Children (age 3 to 16 inclusive) will be included in the patient population if possible, but should not exceed 50% of all patient enrolled. Researchers will first identify the skin donor sites (A and B) for each patient and take baseline digital images and measurements immediately following surgery (Day 1). Trained personnel will apply the dressings provided by the Sponsor for and labeled as A or B by the Sponsor in a random fashion. Typical meticulous wound care and adequate analgesic medical coverage will be provided for the duration of the study. Both the patient and medical staff will be trained on instructions for use of each dressing. The patients will be monitored daily as part of standard procedure while they are in the in-patient setting. If and when patients move to the out-patient setting, they will continue to be monitored at least every-other-day at the study center. On each day (in-patient) or every-other-day (outpatient), the physician will determine whether each skin graft donor site has healed per standard care guidelines (i.e. \> 95% re-epithelization), and pain and adverse events will be monitored. The last study visit will be on Day 24 or on the day when both wounds have been assessed as "healed", whichever comes first.
Participants will consume 2 portions of a product with a nutritional value similar to the study product, one at breakfast and one at dinner. The product will be included in a healthy, normoprotein diet plan. They will be advised to continue their usual physical activity during the 12 weeks of the study.
OBJECTIVE: Chronic subdural hematoma (CSDH) is frequently met in neurosurgical practice and often need urgent surgical treatment in case of neurological deterioration. Different surgical approaches to evacuate CSDH are described in the literature. In our experience, an external drainage system is crucial in order to avoid recurrences. We recently encountered a case of subcutaneous CSF collection after drainage removal. Thus, we developed a simple surgical technique to prevent postoperative CSF leak after subdural drainage system removal.
METHOD: We have developed a technique in which the periosteum is harvested during the surgery prior to the evacuation of the hemorrhage and fixed with sutures on the uncut dura mater opposite and laterally to the exit of the catheter exiting the dural hole caused by the passage of the Jackson-Pratt subdural drainage system. When the drainage catheter is removed, the flap, partially held by the sutures, falls over the hole avoiding CSF leakage. By using this technique, the small dural hole will be covered with the periosteum allowing for natural closure and wound healing hence preventing CSF leakage.
RESULTS: This technique was successfully employed in 21 patients who didn't develop postoperative CSF leakage following CSDH evacuation and removal of subdural drainage system.
CONCLUSION: In this technical note, we describe a safe dura closure technique that we developed to help reduce the risk of postoperative CSF leakage following subdural drainage removal, which can, however, also be applied in all surgeries in which a catheter is placed in the subdural space.
The present invention provides a pure and isolated DNA molecule coding for a polypeptide, having at least 80 percent sequence identity with amino acid sequence being selected from the group consisting of murine RetL3 (sequence id. No. 17) and human RetL3 (id. No. 21), wherein the polypeptide specifically interacts with the receptor protein Ret, and which when it interacts with Ret triggers Ret dimerization and/or autophosphorylation of the tyrosine kinase domain of the receptor protein Ret. There is further provided a polypeptide, being coded by the DNA molecule as well as process for preparing such polypeptide by making use of host cells expriming DNA according to the invention being inserted in the host cells by means of a vector.
The invention discloses preparation of nanometer Chinese medicinal micro-ecological conditioning agent powder with a double-coated spray drying method. The preparation comprises the following steps of: adding a nanometer micro-ecological conditioning agent into starch, and performing primary coating and crushing with an ultrasonic crushing method; adding primary coating slurry into fibroin and chitosan, and performing ball milling; and performing secondary coating to realize nanocrystallization, wherein coating has the functions of suppressing agglomeration and growth of nanometer Chinese medicinal particles and resisting bacteria; and the conditioning agent powder can be used for enhancing immunity and promoting the adsorption of a nanometer Chinese medicine. The micro-ecological conditioning agent is added by extracting active ingredients, i.e., in the form of a micro-ecological conditioning agent solution, and is nano-crystallized by performing ultrasonic crushing and ball milling, so that absorption is facilitated, and an effect is enhanced. The conditioning agent is prepared with a spray drying method. The particle size of the double-coated nanometer Chinese medicinal micro-ecological conditioning agent powder is 20-100 nanometers. The double-coated nanometer Chinese medicinal micro-ecological conditioning agent powder can be applied to micro-ecological dose adjustment. The prepared nanometer Chinese medicinal powder has uniform ingredients and small active compound loss; due to multi-layer coating of particles, powder adsorption is reduced; and by performing process control, particles of different sizes can be obtained, finished powder is crisp, and particulate and tablet medicaments can be prepared.
Discourse intervention in TBI is a nascent area of research, and, to date, there have been only a few studies that have attempted to improve discourse ability in TBI. These prior attempts have been small case studies, produced no change or limited gains, and did not include Veterans with TBI. The proposed project is an early stage discourse treatment development study that will evaluate the feasibility of a novel narrative discourse treatment protocol that builds upon these prior attempts with an all-Veteran participant sample. The first part of the study will consist of initial manual development for the discourse treatment protocol and refinement.

The second part will involve a treatment feasibility trial to obtain information regarding the tolerability, acceptability, and fidelity of the proposed discourse treatment and preliminary data on treatment delivery and assessment methods as well as preliminary information about treatment effects. Forty participants will be randomized to either the discourse treatment group or Treatment as Usual control. Assessments will be conducted at baseline, post-treatment, and at 1-month follow-up.
The present invention provides a method for treating retinopathy of prematurity (ROP) and related retinopathic diseases. The method comprises administering to the retina of a mammal suffering from, or at risk of developing, retinopathy of prematurity or a related retinopathic disease an amount of cells from a vasculotrophic lineage negative hematopoietic stem cell population, effective to promote beneficial physiological revascularization of damaged areas of the retina and to ameliorate damage to the retina caused by the disease. Preferably, the mammal is a human patient. In one preferred embodiment, the lineage negative hematopoietic stem cell population is a lineage negative hematopoietic stem cell population comprising hematopoietic stem cells and endothelial progenitor cells (i.e., Lin~ HSC). In another preferred embodiment, the lineage negative hematopoietic stem cell population is an isolated myeloid-like bone marrow (MLBM) cell population in which the majority of the cells are lineage negative and express CD44 antigen and CD11b antigen. As an alternative, for treatment of newborn infants, a lineage negative hematopoietic stem cell population can be isolated from umbilical cord vein blood.
Patients receive decitabine IV QD over 1 hour on days 1-10, and either ruxolitinib PO BID, fedratinib PO daily, or pacritinib PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
The method of the present invention for analyzing instant POC test results in a telecommunication network comprises performing an instant POC test and obtaining test results. The signal from the test result is detected with a camera (2) in the telecommunications terminal and an image is obtained. The image is interpreted by an artificial neural network ANN, which makes decisions on the analysis of the image. The results of the analysis of the interpreted image are sent to the user interface of the end user. The system of the invention for analyzing the results of an instant POC test comprises the test results of the instant test, a terminal with a camera (2) and a user interface, and software for interpreting the images of the test results taken by the camera. The software uses an artificial neural network to interpret the images and analyze them.
Prospective, observational study will enroll 120 unique pediatric Crohn's disease patients between the ages of 3-20 years among multiple sites. Patients will be naïve to TNF inhibitor. If patient is going to start infliximab or infliximab biosimilar, patient may be enrolled in study. Study length will be from commencement of infliximab until the infusion visit given at least 1 year after initiation. During the study, if the patient fails infliximab or biosimilar, they will be complete study once failure is indicated and discontinued on infliximab or biosimilar. Patients may be on concurrent IBD therapy such as antibiotics, mesalamines, immunomodulators and may continue in study if non-standard induction schedule or changes made during induction or maintenance to dose or frequency. Excluded patients will be those receiving infliximab or biosimilar infusions at home due to need for blood collection at time of infusion, on systemic corticosteroids (topical preparations such as budesonide are allowed), and those who have already undergone significant bowel surgery relating to their Crohn's.

Study visits will take place in conjunction with previously scheduled routine clinic visits or infusion visits. At initial study visit, demographics, medical and surgical history, PARIS classification, PCDAI, weight and height, fecal calprotectin, labs, EGD and colonoscopy report and pathology report, cross-sectional imaging reports and concurrent medications will be obtained and entered. Parameters measured at each study visit will include any obtained labs, weight and height, PARIS classification, PCDAI, infliximab dose (mg/kg) and dose interval. There will be four study visits throughout the course of 1 year after initiating infliximab. At these four visits, blood will be obtained in PAXgene tubes for RNA analysis and serum for banking for SOMAscan analysis.
The parallel rise in obesity and male infertility in modern societies necessitates the identification of susceptibility genes underlying these interconnected health issues. In our study, we conducted a comprehensive search in the OMIM database to identify genes commonly associated with male infertility and obesity. Subsequently, we performed an insilico analysis using the REVEL algorithm to detect pathogenic single nucleotide polymorphisms (SNPs) in the coding region of these candidate genes. To validate our findings in vivo, we conducted a comprehensive analysis of SNPs and gene expression of candidate genes in 200 obese infertile subjects and 240 obese fertile individuals using ARMS-PCR. Additionally, we analyzed 20 fertile and 22 infertile obese individuals using Realtime-qPCR. By removing duplicated queries, we obtained 197 obesity-related genes and 102 male infertility-related genes from the OMIM database. Interestingly, the APOB gene was found in common between the two datasets. REVEL identified the rs13306194 variant as potentially pathogenic with a calculated score of 0.524. The study identified a significant association between the AA (P value = 0.001) genotype and A allele (P value = 0.003) of the APOB rs13306194 variant and infertility in obese men. APOB expression levels were significantly lower in obese infertile men compared to obese fertile controls (p < 0.01). Moreover, the AA genotype of rs13306194 APOB was associated with a significant decrease in APOB gene expression in obese infertile men (p = 0.05). There is a significant association between the Waist-to-Hip Ratio (WHR) and LH with infertility in the obese infertile group. These results are likely to contribute to a better understanding of the causes of male infertility and its association with obesity.
The control group will receive a general full body massage referred to as a Global Relaxation massage. The massage technique used here will be relaxation massage, avoiding the breast/chest/arm area. This includes light kneading and stroking in order to restore a sense of well- being. The relaxation massage will also be twice a week at 30 minutes per massage for a period of 2 months, avoiding the area of the affected shoulder/shoulders. In this way they are still being seen and touched by a massage therapist, without receiving the intervention treatment.
PROBLEM TO BE SOLVED: To obtain an external preparation for protecting and treating skin, having improved retention of fat-soluble medicine in a liposome, by adding a polymer compound to the exterior of a liposome holding a greasy (fat-soluble) medicine. SOLUTION: This external preparation is obtained by adding a liposome containing a vitamin E and a fat-soluble medicine such as glycyrrhetic acid to a substrate containing a polymer compound such as an uncharged cellulose. The amount of the polymer compound is 0.001-10 pts.wt. based on 1 pt.wt. of the liposome and the amount of the fat-soluble medicine is 0.0001-0.05 pt.wt. and that of the polymer compound is 0.001-0.1 pt.wt based on 1 pt.wt. of the external preparation. The external preparation is a liquid or semisolid lotion having about 0.05-10 Pa.s viscosity and is rubbed into the skin in use. Since the fat-soluble medicine is efficiently retained in the liposome, the medicine is advantageous in terms of durability of medicinal effects.  The medicine is effective as a skin protecting agent, therapeutic agent, humectant, antiinflammatory agent, etc., depending upon the kind of the medicine.
Oral iron is absorbed most efficiently when administered between meals. Iron is critical for normal hemoglobin synthesis to maintain oxygen transport energy production and proper function of cells. Adequate amounts of iron are necessary for effective erythropoiesis. Iron also serves as a cofactor of several essential enzymes, including cytochromes, which are involved in electron transport. Folic acid is required for nucleoprotein synthesis and the maintenance of normal erythropoiesis. Folic acid is the precursor of tetrahydrofolic acid, which is involved as a cofactor for transformylation reactions in the biosynthesis of purines and thymidylates of nucleic acids. Deficiency of folic acid may account for the defective deoxyribonucleic acid (DNA) synthesis that leads to megaloblast formation and megaloblastic macrocytic anemias. Vitamin B 12is essential to growth, cell reproduction, hematopoiesis, nucleic acid, and myelin synthesis. Deficiency may result in megaloblastic anemia or pernicious anemia.
Cosmetic products contain as active component at least one substance obtd. from fish eggs. A variety of substances can be obtd. including amino acids promoting the regeneration of tissues, lipids, phospholipids, glucides and vitamins. The product may be in the form of creams, lotions, shampoos, soaps etc. The substances may be isolated by physical, chemical, physicochemical or biological methods, such as lyophilisation or extraction with solvents, such as water, an alcohol, ethylene glycol, or jet ether. The substance is a total extract or a fraction obtd. by successive extraction with successive solvents. The fish eggs are pref. salmon. eggs. The cosmetic products pref. contain a lipid extract or a glycolysate extract of fish eggs.
Papaverine Hydrochloride, USP, is the hydrochloride of an alkaloid obtained from opium or prepared synthetically. It belongs to the benzylisoquinoline group of alkaloids. It does not contain a phenanthrene group as do morphine and codeine.

Papaverine Hydrochloride, USP, is 6,7-dimethoxy-1- veratrylisoquinoline hydrochloride and contains, on the dried basis, not less than 98.5% of C 20H 21NO 4•HCl. The molecular weight is 375.85. The structural formula is as shown. 

Papaverine Hydrochloride occurs as white crystals or white crystalline powder. One gram dissolves in about 30 mL of water and in 120 mL of alcohol. It is soluble in chloroform and practically insoluble in ether.

Papaverine Hydrochloride Injection, USP, is a clear, colorless to pale-yellow solution.

Papaverine Hydrochloride, for parenteral administration, is a smooth-muscle relaxant that is available in vials containing 30 mg/mL. Each vial also contains edetate disodium 0.005%.

pH may be adjusted with sodium citrate and/or citric acid.
Chronic heart failure is one of the most common reasons for hospitalization. Current risk stratification is based on ejection fraction, whereas many arrhythmic events occur in patients with relatively preserved ejection fraction. We aim to investigate the mechanistic link between proarrhythmic abnormalities, reduced contractility and diastolic dysfunction in heart failure, using electromechanical modelling and simulations of human failing cardiomyocytes. We constructed, calibrated and validated populations of human electromechanical models of failing cardiomyocytes, that were able to reproduce the prolonged action potential, reduced contractility and diastolic dysfunction as observed in human data, as well as increased propensity to proarrhythmic incidents such as early afterdepolarization and beat-to-beat alternans. Our simulation data reveal that proarrhythmic incidents tend to occur in failing myocytes with lower diastolic tension, rather than with lower contractility, due to the relative preserved SERCA and sodium calcium exchanger current. These results support the inclusion of end-diastolic volume to be potentially beneficial in the risk stratifications of heart failure patients.
The present invention is directed to oral care ULTRAMULSIONTM based oral care products, including, toothpastes, treated flosses and dental stimulators, interdental coating substances, oral rinses, mouth/throat conditioning internal treatment products, and anti-gingivitis products. All of these products are improved when an ULTRAMULSIONTM dispersion containing silicone and a surfactant is used as taught herein. The ULTRAMULSIONTM dispersions of the present invention combine certain characteristics of emulsions with certain features of microemulsions. Like conventional emulsions, they are two phase systems comprising a silicone dispersed in a continuous, surfactant phase, wherein the silicone is insoluble in the surfactant. Unlike conventional emulsions, but like microemulsions, these dispersions are stable.  Unlike microemulsions, but like conventional emulsions, mechanical work is required to form ULTRAMULSIONTM dispersions. Unlike microemulsions, but like conventional emulsions, these ULTRAMULSIONTM dispersions are not formed spontaneously. Like conventional emulsions, the ULTRAMULSIONTM dispersions do not contain a cosolvent commonly found in microemulsions.
The invention discloses application of STM2457 in preparation of a medicine for preventing and treating pulmonary arterial hypertension, and relates to the technical field of biological medicines. The invention provides application of STM2457 in preparation of a medicament for treating pulmonary arterial hypertension. The invention also provides application of STM2457 in preparing medicines and/or health-care products for pulmonary vascular remodeling. The invention discovers that STM2457 can relieve and improve the occurrence and the occurrence of pulmonary arterial hypertension of mice. The result shows that STM2457 serving as an inhibitor of METTL can obviously inhibit hypoxia or inflammatory factor-induced smooth muscle cell proliferation and invasion through the m  6  A modification level of pulmonary artery smooth muscle, obviously improve the occurrence and development of pulmonary artery hypertension, and obviously reduce the pulmonary artery pressure and right heart reconstruction of a hypoxia-induced mouse pulmonary artery hypertension model. The proposal of the invention overcomes the problem that the prior pulmonary arterial hypertension lacks effective therapeutic drugs.
Replacing nonbiodegradable plastics with environmentally friendly cellulose materials has emerged as a key trend in environmental protection. This study highlights the development of a strong and hydrophobic micro-nano fibrillated cellulose paper (MNP) through the incorporation of micro-nano fibrillated cellulose fiber (MNF) and chitin nanocrystal (Ch), followed by the impregnation of polymethylsiloxane (PMHS). A low-acid, heat-assisted colloidal grinding strategy was employed to prepare MNF with a high aspect ratio effectively. Ch was incorporated as a reinforcing matrix into the cellulose fiber scaffold through straightforward mechanical mixing and mechanical hot-pressing treatments. Compared to pure MNP, the 5Ch-MNP exhibited a 25 % improvement in tensile strength, reaching 170 MPa, and showed enhanced barrier properties against oxygen and water vapor. The impregnation of PMHS rapidly confers environmentally resistant hydrophobic properties to 1 % PMHS-5Ch-MNP, leading to a water contact angle exceeding 112°, and a 290 % increase in tensile strength under wet conditions. Additionally, the paper demonstrated excellent antibacterial adhesion properties, with the adhesion rates for E. coli and S. aureus exceeding 98 %. This study successfully produced functional cellulose paper with remarkable mechanical properties and barrier properties, as well as hydrophobicity, using a simple, efficient, and environmentally friendly method, making it a promising substitute for petroleum-based plastics.
NEW MATERIAL:A compound (salt) shown by formula I [A is group shown by formula II (R1 and R2 are alkyl, substituted alkyl, cycloalkyl, aralkyl, etc.), morpholino, etc.; Ra and Rb are H or methyl; X is O or S; m is 2-8 integer; n is 0 or 1]. EXAMPLE:7-N-(2-Methylaminocarbonylthioethyl)mitomycin C. USE:An antitumor agent. PREPARATION:For example, an amine compound shown by the formula AH is reacted with a halocarbonic acid ester to give a carbamic acid haloalkyl ester shown by formula III (Hal is halogen), which is reacted with a mercaptoalkylamine to give a compound shown by formula IV. Then this compound is reacted with a 7-methoxymitomycin shown by formula V to give a compound shown by formula I.